September 02, 2009
The IMB has published a Drug Safety Newsletter on the antiviral medicines Tamiflu and Relenza, which provides an overview of relevant regulatory activities and associated recommendations for safe use of these medicines. The IMB has developed a web-based system for reporting of adverse reactions by healthcare professionals, patients and the public during the pandemic. This is accessible via a designated ‘pandemic webpage' on the IMB website at http://www.imb.ie/EN/Medicines/Pandemic-H1N1-2009.aspx. Please use the contact details below with any queries you may have in relation to the newsletter or the reporting of adverse reactions: Tel: 353-1-676 4971 Fax: 353-1-634 3514 Email: imbpharmacovigilance@imb.ie Pharmacovigilance Section, Irish Medicines Board, Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland
Back to News List